Global Cell Therapy Market & Clinical Pipeline Out

Dublin, Feb. 03, 2017 (GLOBE NEWSWIRE) -- Research and Markets has announced the addition of the "Global Cell Therapy Market & Clinical Pipeline Outlook 2022" report to their offering. The Global Cell Therapy Market & Clinical Pipeline Outlook 2022 report gives comprehensive insight on the ongoing clinical and nonclinical trends in the global cell therapy market.

Report analyzes the need and the application of cell therapy in multiple therapeutic areas along with the mechanism and delivery methods for cell therapy based treatment. The parameters impacting the growth of the market and the corresponding challenges limiting the commercialization of cell therapies are explained in the report. The idea of cell therapy was in pharmaceutical industry for several decades but significant development was not made due to technological challenges. In recent years, cell therapy has gained widespread acceptance among physicians and patients due to its ability to treat various diseases. Several decades of research and development has allowed the investigators to come forth with solutions which can't be provided by conventional therapeutics. Theoretically, it could be used to cure plethora of diseases but underdeveloped technology has limited its usage to limited indications. Several indications have been found to be curable with the help of cell therapies and indications are expected to be increased in near future. Cerebral disorders like Parkinson's disease and Alzheimer's disease are under investigation for treatment with the help of cell therapies. They are also being investigated for cardiovascular disease in which their aim is to restore normal heart functions. Investigators are also trying to find their safety and efficacy in treating various malignancies. On-going research is also aimed at curing metabolic disorder like diabetes mellitus type 1 in which patients tends to lack insulin production. Investigators are trying to restore the function of liver and kidney by supplementing them with modified cell of respective origins. Several clinical trials have been instigated across the globe in which their efficacy against different disease is being studies. Global Cell Therapy Market & Clinical Pipeline Outlook 2022 Highlights: - Introduction & Classification of Cell Therapies - Mechanism of Cell Therapy - Global Cell Therapy Market Analysis - Role of Stem Cells in Cell Therapy - Global Cell Therapy Clinical Pipeline by Country, Indication & Phase - Global Cell Therapy Clinical Pipeline: 476 - Marketed Cell Therapies: 20 Key Topics Covered: 1. Introduction to Cell Therapy 2. Necessity for Cell Therapy Treatment 2.1 Emergence of Stem Cell Research 2.2 Benefits of Using the Stem Cell for Research & Treatment 3. Application of Stem Cells in Cell Therapy 3.1 Stem Cells Ability to Differentiate 3.1.1 Totipotent Stem Cells 3.1.2 Pluripotent Stem Cells 3.1.3 Multipotent Stem Cells 3.1.4 Unipotent Stem Cells 3.2 Origin of Stem Cells 3.2.1 Embryonic Stem Cells 3.2.2 Adult Stem Cells 3.2.3 Induced Pluripotent Stem Cells (iPSCs) 4. Applications of Cell Therapy by Therapeutic Area 4.1 Cell Therapy for Cardiovascular Diseases 4.2 Cell Therapy for Neurological Disorders 4.3 Cell Therapy for Inflammatory Diseases 4.4 Cell Therapy for Diabetes 4.5 Cell Therapy for Cancer 4.6 Cancer Stem Cells Therapy 5. Mechanism of Cell Therapy 5.1 Two Major Mechanism Principles of Stem Cell Based Therapy 5.2 Mechanism of Action in Alzheimer's Diseases 6. Delivery Method of Cell Based Therapy 6.1 Outline to Delivery Methods 6.2 Direct Delivery Methods 6.3 Indirect Delivery of the Cells by Using the Carrier 7. Mechanism of Cell Therapy Treatment 7.1 Allogeneic Stem Cell Therapy 7.2 Autologous Stem Cell Therapy 8. Global Cell Therapy Market Overview 8.1 Current Market Scenario 8.2 Current Trends of Cell Therapy in Global Market 8.3 Global Cell Therapies Clinical Pipeline Overview 9. Global Cell Therapy Market by Region 9.1 North America 9.2 Europe 9.3 Asia 9.4 Rest of the World 10. Global Cell Therapy Market Dynamics 10.1 Favorable Market Parameters 10.2 Factors Limiting Market Growth 11. Global Cell Therapy Market Future Prospect 12. Global Cell Therapies Clinical Pipeline by Company, Indication & Phase 12.1 Unknown 12.2 Research 12.3 Preclinical 12.4 Clinical 12.5 Phase-0 12.6 Phase-I 12.7 Phase-I/II 12.8 Phase-II 12.9 Phase-II/III 12.10 Phase-III 12.11 Preregistration 12.12 Registered 13. Marketed Cell Therapies Clinical Insight by Company & Indication 13.1 T-Lymphocyte Cell Therapy (Immuncell-LC) 13.2 Muscle-Derived Autologous Stem Cell Therapy (MyoCell & MyoCell SDF-1) 13.3 Azficel-T (Laviv) 13.4 Sipuleucel-T (Provenge) 13.5 Placental Derived Mesenchymal Stem Cell Therapy - Osiris Therapeutics 13.6 Remestemcel-L (Prochymal & TEMCELL HS Inj.) 13.7 Autologous Mesenchymal Stem Cell Therapy - Pharmicell 13.8 Autologous Cultured Chondrocytes (MACI) 13.9 Mesenchymal Stem Cell Therapy for Cartilage Repair (Cartistem) 13.10 Leukocyte Cell Therapy (CureXcell) 13.11 Adipose Stem Cell Therapy (Adipocell (Anterogen), Cupistem & Queencell) 13.12 Allogeneic Cultured Keratinocytes and Fibroblasts (Gintuit) 13.13 Autologous Cultured Chondrocyte Implant (Carticel) 13.14 Autologous Cultured Chondrocytes (CHONDRON) 13.15 Autologous Chondrocytes (BioCart & BioCartII) 13.16 Amniotic Cell Therapy (NuCel) 13.17 Dendritic Cell-Activated Cytokine-Induced Killer Cells - Shanghai Jia Fu Medical 13.18 Autologous Cultured Chondrocytes (Chondrotransplant DISC) 13.19 Autologous Cultured Myoblasts and Fibroblasts (Urocell) 13.20 Human Skin Replacement (CellSpray & CellSpray XP) 14. Competitive Landscape 14.1 AlloCure 14.2 Arteriocyte Medical Systems 14.3 Athersys Inc. 14.4 Baxter Healthcare Corporation 14.5 Bone Therapeutics 14.6 Celgene Corporation 14.7 Cell Medica 14.8 Cellerant Therapeutics 14.9 FibrocellScinence 14.10 Forticell Bioscience 14.11 Genzyme Corporation 14.12 Green Cross Cell 14.13 Histogenics Corporation 14.14 InnovacellBiotechnologie AG 14.15 Intrexon Corporation 14.16 Intercytex 14.17 ISTO Technologies 14.18 Macrocure 14.19 Mesoblast 14.20 Molmed 14.21 Nuo Therapeutics Inc 14.22 OmniCyte 14.23 Opexa Therapeutics 14.24 Organogenesis 14.25 Pharmicell 14.26 TCA Cellular Therapy 14.27 Stem Cell Inc. 14.28 Teva Pharmaceuticals 14.29 Tigenix 14.30 Vericel Corporation For more information about this report visit http://www.researchandmarkets.com/research/m7...lobal_cell

CONTACT: Research and Markets Laura Wood, Senior Manager press@researchandmarkets.com For E.S.T Office Hours Call 1-917-300-0470 For U.S./CAN Toll Free Call 1-800-526-8630 For GMT Office Hours Call +353-1-416-8900 U.S. Fax: 646-607-1907 Fax (outside U.S.): +353-1-481-1716 Related Topics: Genomics